Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Avelox (moxifloxacin) IV and tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – November 2009

 

Summary View

 

ADVERSE REACTIONS

Postmarketing Adverse Event Reports
  • include the possibility of the exacerbation of the symptoms of myasthenia gravis associated with the use of moxifloxacin.
-
-